Literature DB >> 12824284

A model for modulation of leptin activity by association with clusterin.

Tarek M Bajari1, Vera Strasser, Johannes Nimpf, Wolfgang J Schneider.   

Abstract

Transport, biological action, and clearance of leptin are subject to modulation by plasma components responsible for the formation of the so-called "bound" fraction of serum leptin. Candidates for modulators have been identified previously, but mechanisms for their action, and thus their physiological roles, have remained unclear. Here we have obtained evidence for a role of serum-borne clusterin in leptin biology and have delineated a possible mechanism for its action. We demonstrate complex formation between clusterin and leptin by several approaches and show that the binary complex retains the ability to transduce the leptin signal via binding to the leptin receptor and activation of the Janus kinase/signal transducer and activator of transcription pathway. The interaction of leptin with clusterin does not require additional serum components. Furthermore, and importantly for modulation of the bioactivity of leptin, uptake of leptin present in the complex can be mediated by members of the low density lipoprotein (LDL) receptor family, i.e., apolipoprotein receptor type-2 and the very LDL receptor, which here are shown to efficiently endocytose both free and leptin-associated clusterin. Thus, bioavailability of leptin at a given tissue site may be determined by the levels of clusterin and/or by the relative distribution of certain relatives of the LDL receptor vis-à-vis active leptin receptors.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12824284     DOI: 10.1096/fj.02-1106fje

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  19 in total

Review 1.  Quality control of protein folding in extracellular space.

Authors:  Justin J Yerbury; Elise M Stewart; Amy R Wyatt; Mark R Wilson
Journal:  EMBO Rep       Date:  2005-12       Impact factor: 8.807

2.  Reanalysis of parabiosis of obesity mutants in the age of leptin.

Authors:  Wenwen Zeng; Yi-Hsueh Lu; Jonah Lee; Jeffrey M Friedman
Journal:  Proc Natl Acad Sci U S A       Date:  2015-07-06       Impact factor: 11.205

3.  Clusterin and chemotherapy sensitivity under normoxic and graded hypoxic conditions in colorectal cancer.

Authors:  David Kevans; Sheeona Gorman; Miriam Tosetto; Kieran Sheahan; Diarmuid O'Donoghue; Hugh Mulcahy; Jacintha O'Sullivan
Journal:  J Gastrointest Cancer       Date:  2012-06

4.  Clusterin facilitates in vivo clearance of extracellular misfolded proteins.

Authors:  Amy R Wyatt; Justin J Yerbury; Paula Berghofer; Ivan Greguric; Andrew Katsifis; Christopher M Dobson; Mark R Wilson
Journal:  Cell Mol Life Sci       Date:  2011-04-20       Impact factor: 9.261

5.  Clusterin signals via ApoER2/VLDLR and induces meiosis of male germ cells.

Authors:  Muhammad Assad Riaz; Angelika Stammler; Mareike Borgers; Lutz Konrad
Journal:  Am J Transl Res       Date:  2017-03-15       Impact factor: 4.060

Review 6.  The physiological roles of apolipoprotein J/clusterin in metabolic and cardiovascular diseases.

Authors:  S Park; K W Mathis; I K Lee
Journal:  Rev Endocr Metab Disord       Date:  2014-03       Impact factor: 6.514

7.  Clusterin and LRP2 are critical components of the hypothalamic feeding regulatory pathway.

Authors:  So Young Gil; Byung-Soo Youn; Kyunghee Byun; Hu Huang; Churl Namkoong; Pil-Geum Jang; Joo-Yong Lee; Young-Hwan Jo; Gil Myoung Kang; Hyun-Kyong Kim; Mi-Seon Shin; Claus U Pietrzik; Bonghee Lee; Young-Bum Kim; Min-Seon Kim
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

8.  Clusterin/ApoJ enhances central leptin signaling through Lrp2-mediated endocytosis.

Authors:  Kyunghee Byun; So Young Gil; Churl Namkoong; Byung-Soo Youn; Hu Huang; Mi-Seon Shin; Gil Myoung Kang; Hyun-Kyong Kim; Bonghee Lee; Young-Bum Kim; Min-Seon Kim
Journal:  EMBO Rep       Date:  2014-05-12       Impact factor: 8.807

9.  Circulating ApoJ is closely associated with insulin resistance in human subjects.

Authors:  Ji A Seo; Min-Cheol Kang; Theodore P Ciaraldi; Sang Soo Kim; Kyong Soo Park; Charles Choe; Won Min Hwang; Dong Mee Lim; Olivia Farr; Christos Mantzoros; Robert R Henry; Young-Bum Kim
Journal:  Metabolism       Date:  2017-10-03       Impact factor: 8.694

10.  A common haplotype lowers PU.1 expression in myeloid cells and delays onset of Alzheimer's disease.

Authors:  Kuan-Lin Huang; Edoardo Marcora; Anna A Pimenova; Antonio F Di Narzo; Manav Kapoor; Sheng Chih Jin; Oscar Harari; Sarah Bertelsen; Benjamin P Fairfax; Jake Czajkowski; Vincent Chouraki; Benjamin Grenier-Boley; Céline Bellenguez; Yuetiva Deming; Andrew McKenzie; Towfique Raj; Alan E Renton; John Budde; Albert Smith; Annette Fitzpatrick; Joshua C Bis; Anita DeStefano; Hieab H H Adams; M Arfan Ikram; Sven van der Lee; Jorge L Del-Aguila; Maria Victoria Fernandez; Laura Ibañez; Rebecca Sims; Valentina Escott-Price; Richard Mayeux; Jonathan L Haines; Lindsay A Farrer; Margaret A Pericak-Vance; Jean Charles Lambert; Cornelia van Duijn; Lenore Launer; Sudha Seshadri; Julie Williams; Philippe Amouyel; Gerard D Schellenberg; Bin Zhang; Ingrid Borecki; John S K Kauwe; Carlos Cruchaga; Ke Hao; Alison M Goate
Journal:  Nat Neurosci       Date:  2017-06-19       Impact factor: 24.884

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.